

RNS Number : 1097G
EKF Diagnostics Holdings PLC
01 November 2018

EKF Diagnostics Holdings plc
("EKF" or the "Company")

**Update regarding AIM admission of RenalytixAI and planned
change of EKF's nominated adviser**

EKF Diagnostics Holdings plc (AIM: EKF) announces that, further to the announcement on 31 October confirming that Renalytix AI plc ("RenalytixAI") had successfully raised £22.25 million in gross proceeds, RenalytixAI will now be admitted to trading on AIM on 6 November 2018. An updated Schedule One announcement is expected to be issued on 2 November 2018.

Participants in the fundraising will be contacted by N+1 Singer, the Company or Link Asset Services to confirm updated settlement instructions.

EKF and N+1 Singer, the Company's current nominated adviser and broker, have agreed that in order to preserve the independence of its nominated adviser, EKF will appoint a new nominated adviser after the admission of RenalytixAI. A further announcement will be made in this regard in due course.

N+1 Singer will continue to act as broker to EKF.

Enquiries:

EKF Diagnostics Holdings plc

Christopher Mills, Non-Executive Chairman **Tel: 029 2071 0570**
Julian Baines, CEO
Richard Evans, FD & COO

N+1 Singer (Nominated Adviser & Broker) Tel: 020 7496 3000

Aubrey Powell / Lauren Kettle / George Tzimas (Corporate
Finance)
Tom Salvesen (Corporate Broking)

Walbrook PR Limited

Paul McManus / Lianne Cawthorne

Tel: 020 7933 8780 or ekf@walbrookpr.com

Mob: 07980 541 893 / 07584 391 303

**About EKF Diagnostics Holdings
plc**

www.ekfdiagnostics.com

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDDFLFBVFFLFB admin Update regarding AIM admission of RenalytixAI 28218023 A Thu, 11/01/2018 - 17:30 LSE RNS Company Announcement - General EKF